Clinical Research Directory

Inclusion Criteria: 1. Aged 18 years or older 2. AML diagnosis according to the ELN guidelines, excluding M3 3. Signed Informed consent, if applicable 4. Treatment initiation with novel drugs in monotherapy or combination, in accordance with the AIFA authorizations, from the AIFA registration up to 31.12.2027 with particular attention to: * patients affected by FLT3-mutated AML treated with gilteritinib. * patients affected by IDH-mutated AML treated with IDH inhibitors. * patients affected by AML in maintenance therapy with oral azacytidine. * patients affected by AML treated with glasdegib. * patients affected by AML treated with gemtuzumab ozogamicin. * other novel drugs or combination for the treatment of AML approved during the study period. Exclusion Criteria: Patients included in interventional clinical trials.